Janssen Pharmaceuticals will pay Hawaii $2.7 million as part of a landmark $181 million agreement to settle claims about deceptive marketing. 

Hawaii joined with 35 other states and the District of Columbia in filing suit against Janssen, a subsidiary of Johnson and Johnson. 

Excerpts from a state press release: 

In a suit filed today by the Office of Consumer Protection, the State alleged that Janssen improperly marketed the antipsychotic drugs Risperdal, Risperdal Consta, Risperdal M-Tab and Invega.   

… After an extensive four-year investigation, Janssen agreed to change not only how it promotes and markets its atypical antipsychotics, but also agreed to refrain from any false, misleading or deceptive promotion of the drugs.  In addition to the record setting payment, the settlement targets specific concerns identified in the investigation.  The settlement agreement restricts Janssen from promoting its atypical antipsychotic drugs for “off-label” uses that the U.S. Food and Drug Administration (FDA) has not approved.